As part of our series focussing on available medicines in Australia, we have added a product review of use of selinexor for the treatment of relapsed or refractory multiple myeloma.
This review discusses relapsing remitting multiple myeloma, the need for novel therapies, indications and dosage, contraindications and a series of clinical studies featuring selinexor use. It also provides commentary from Professor Hang Quach, Director of Clinical Haematology and Clinical Haematology Research at St.Vincent’s Hospital Melbourne.
Please login below to download this issue (PDF)